Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Catalent will expand its Argentinian site in Loma Hermosa, Buenos Aires.
read more
Catalent will provide support for the development, manufacturing, and clinical supply of Editas Medicine’s current and future portfolio of in vivo CRISPR medicines and engineered cell medicines.
read more
Monday, February 22, 2021
Catalent recently signed a multi-year commercial supply agreement with Aurinia for LUPKYNIS, a drug to treat adult patients with lupus nephritis.
read more
Catalent announced it is investing up to $40 million at its manufacturing facility in Winchester, Kentucky.
read more
Catalent, Inc. announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the ...
read more
Catalent announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022.
read more
Catalent announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer.
read more
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced two senior appointments to further strengthen its global biologics ...
read more
Thursday, February 13, 2020
Catalent announced the appointment of Jim Walter as Vice President of Operations for its Oral and Specialty Delivery business.
read more
Tuesday, December 01, 2020
Catalent announced the appointment of Behzad Mahdavi, Ph.D., MBA, as Vice President of Open Innovation, Biologics, Cell and Gene Therapy.
read more
Thursday, January 22, 2015
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Mitsubishi Gas Chemical Company, Inc. (MGC), today jointly announced that they ...
read more
Thursday, September 03, 2020
Catalent announced it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.
read more
Catalent announced the launch of a next-generation cell line development technology, GPEx® Lightning. Leveraging Catalent’s proven GPEx expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx ...
read more
Catalent plans to invest $30 million at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.
read more
Catalent held a ground breaking ceremony at its Bloomington, Indiana site to mark the start of construction on a $112 million drug product manufacturing facility.
read more